Androgen-Associated Hepatoma in a Hemodialysis Patient

Zevin, D; Turani, H; Cohen, Amos; Levi, J

doi:10.1159/000182388

Cited by 18 publications

(7 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The androgen preparation was nandrolone decanoate, which is efficacious and without appreciable side effects [3,11]. Liver dysfunction, peliosis hepatis and hepatocellular carcinoma have been reported in patients receiving 17-alkyiated androgens [12][13][14][15][16], Nandrolone decanoate is not a 17-alkylated androgen and no cases of hepatic injury have been described with the use of this drug [17][18][19][20][21][22],…”

Section: Introductionmentioning

confidence: 99%

Evolution of Serum Erythropoietin after Androgen Administration to Hemodialysis Patients: A Prospective Study

Teruel

Marcén²,

Navarro³

et al. 1995

Nephron

View full text Add to dashboard Cite

A prospective study of the evolution of serum erythropoietin level after androgen therapy was carried out in a group of 25 male patients on chronic hemodialysis treatment with nonferropenic anemia (serum ferritin > 50 ng/ml). The androgen used was nandrolone decanoate (200 mg/week intramuscularly, for 6 months). There was an increase of serum erythropoietin, that reached statistical significance in the 2nd week of treatment (8.6 ± 6.4 vs. 14.2 ± 9.8 mIU/ ml, p < 0.05), and a stabilization after 1 month (1 month: 17.8 ± 11.2 mIU/ ml, 6 months: 19.6 ± 14.9 mlU/ml). The hemoglobin also experienced a parallel increase to that observed in serum erythropoietin (basal value: 8 ± 0.9 g/ dl; at 1 month postandrogen: 9.2 ± 1.3 g/dl, p < 0.001; at 6 months: 10.7 ± 1.8 g/dl, p < 0.001). According to their response of serum erythropoietin the patients were divided into responders (15 patients) and nonresponders (10 patients). There were no differences between them concerning age, basal levels of serum erythropoietin and hemoglobin, and dose of nandrolone decanoate in relation to body weight. The evolution of hemoglobin was similar in both groups, and a correlation between serum erythropoietin and hemoglobin was not observed in the responder group. Fourteen patients were studied after androgen was discontinued. The serum erythropoietin returned to basal levels 6 weeks after the last dose of nandrolone decanoate (7.7 ± 5.4 mlU/ml). However, hemoglobin was above the basal levels 16 weeks after discontinuing androgen (9.5 ± 1.1 g/dl, p < 0.05), with no differences between the responder and nonresponder group. In conclusion, the hematopoietic effect of androgen in patients with chronic renal failure is independent of its action on the serum erythropoietin levels. The increase in the serum erythropoietin observed in 60% of patients is not the cause of the improvement in anemia and may be considered as an epiphenomenon.

show abstract

Section: Introductionmentioning

confidence: 99%

Evolution of Serum Erythropoietin after Androgen Administration to Hemodialysis Patients: A Prospective Study

Teruel

Marcén²,

Navarro³

et al. 1995

Nephron

View full text Add to dashboard Cite

show abstract

“…Lower level of serum albumin in this study is attributed to less intake of protein than the commonly recommended protein intake. It is reported that use of androgen induces liver dysfunction, peliosis hepatis and hepatoma when 17-alkylated androgen was used 22 – 25 ) , but such liver damages were not reported when nandrolone decanoate as a derivative of 19-nortestosterone was used 3 , 8 , 9 , 26 , 27 ) . No finding of liver dysfunction was observed in this study.…”

Section: Discussionmentioning

confidence: 99%

Effects of Adjuvant Androgen on Anemia and Nutritional Parameters in Chronic Hemodialysis Patients Using Low - dose Recombinant Human Erythropoietin

Lee

Ahn

Song

2002

Korean J Intern Med

View full text Add to dashboard Cite

Background:Recombinant human erythropoietin (epoetin) has greatly contributed to improvement of the anemia of chronic renal failure patients on hemodialysis. However, the reduced erythropoietic effect to epoetin and its high cost have induced lots of supplementary treatments. Therefore, we performed a prospective study to evaluate the effects of adjuvant low-dose androgen therapy in patients using a lower-dose of epoetin than the commonly recommended dose on anemia and the nutritional parameters.Methods :17 patients of hemoglobin (Hgb) less than 9 g/dL even after being treated with 1,000 U epoetin subcutaneously (s.c.) 3 times per week on a stable status for more than 6 months, who were on hemodialysis at our institution were examined. They were injected with the same dose of epoetin s.c. and nandrolone decanoate 100 mg intramuscularly (i.m) weekly for another 6 months. Blood test was performed every month before therapy for 6 months and after therapy for 6 months and the mean values were reviewed for comparison.Results:Hgb (7.75±0.9 vs 8.99±1.39 g/dL, p <0.01) and hematocrit (Hct) (23.68±2.85 vs 26.66±3.91%, p <0.01) were apparently changed before and after adjuvant therapy. Hgb and Hct, weekly dose of epoetin were not statistically different in 9 male patients before and after adjuvant therapy. The weekly dose of epoetin was not statistically different in 8 female patients, but Hgb and Hct (8.02±0.6 vs 9.72±1.31 g/dL, 24.54±1.7 vs 28.74±3.06%, p <0.01) were statistically different before and after adjuvant therapy. In comparison between male and female groups, weekly doses of epoetin and nandrolone decanoate were significantly greater in the female group than the male group (epoetin: 50.66±6.23 vs 61.18±8.76 U/kg/week, nandrolone decanoate: 1.69±0.2 vs 2.04±0.29 mg/kg/week, p <0.05).Conclusion :Our data show that the adjuvant androgen therapy is effective for the anemia of hemodialysis patients who did not recover from anemia even after being continuously treated with low-dose epoetin.

show abstract

“…Tumores hepáticos têm sido associados com o uso de esteróides anabolizantes em indivíduos submetidos a tratamento clínico com estas drogas [74][75][76][77][78][79][80] . Estes tumores são geralmente benignos 75,77,78,80 , mas têm sido observadas lesões malignas associadas com o uso dessas drogas 74,79,80 . A possível relação causa-efeito desta associação entre o uso de esteróides e o desenvolvimento de tumores é reforçada pelo relato da regressão do tumor após interrupção do tratamento com esteróides 76 .…”

Section: Efeitos Adversosunclassified

“…Tem havido relatos de que as provas de função hepática estão inalteradas com o uso de esteróides em alguns estudos envolvendo treinamento 31,36,41,48 e alteradas em outros estudos semelhantes 45,47 e em exames realizados em atletas que sabidamente estavam em uso de esteróides anabolizantes 11,48,59 . Contudo, as lesões de peliose hepática e tumores hepáticos nem sempre produzem anormalidades nesses exames 65,[74][75][76][77]80 e alguns autores sustentam que são necessárias cintilografias hepáticas, ultra-sonografias ou tomografias computadorizadas para este diagnóstico 74,75,83 .…”

Section: Efeitos Adversosunclassified

O uso de esteróides anabolizantes nos esportes

1998

Rev Bras Med Esporte

View full text Add to dashboard Cite

Androgen-Associated Hepatoma in a Hemodialysis Patient

Cited by 18 publications

References 11 publications

Evolution of Serum Erythropoietin after Androgen Administration to Hemodialysis Patients: A Prospective Study

Evolution of Serum Erythropoietin after Androgen Administration to Hemodialysis Patients: A Prospective Study

Effects of Adjuvant Androgen on Anemia and Nutritional Parameters in Chronic Hemodialysis Patients Using Low - dose Recombinant Human Erythropoietin

O uso de esteróides anabolizantes nos esportes

Contact Info

Product

Resources

About